Glaxo Smith Kline

Type
Internal restructuring
Country
United Kingdom
Region
East (England); Essex; West Essex
Location of affected unit(s)
Harlow
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
380 jobs
Number of planned job losses
Job loss
Announcement Date
9 February 2010
Employment effect (start)
9 February 2010
Foreseen end date

Description

380 jobs to go as GlaxoSmithKline closes its research unit in Harlow, Essex. The losses come as projects for pain relief, anxiety and depression drugs end, and no further research is planned. The company says a consultation period is under way, and that to acheive a £500m saving by 2012 it would continue to restructure, but with a minimum of job losses. The firm announced a 12% rise in annual profit on 4 February 2010. No details were given regarding when the job losses would be completed by.

Sources

  • 9 February 2010: BBC Website

Citation

Eurofound (2010), Glaxo Smith Kline, Internal restructuring in United Kingdom, factsheet number 70186, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/70186.